TriSalus Life Sciences, Inc.
Close on Oct 19, 2026
- Market cap
- $205.79M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $11.40M | $-0.16 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | $8.90M | $0.03 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | $13.20M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $11.60M | $-0.96 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $11.20M | $-0.27 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | $9.20M | $-0.39 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 23, 2025 | Before market open | $8.30M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $7.30M | $-0.12 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 5, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| full-year 2026 revenue guidance | full-year 2026 | $54.00M to $57.00M | Maintained |
| growth | full-year 2026 | 19% to 26% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements TriSalus Life Sciences filed with the SEC
TriSalus Life Sciences Reports Second Quarter 2026 Results
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Reports First Quarter 2026 Results Commercial and Clinical Progress for Facilitating Long-Term Growth
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Life Sciences Proposes Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Life Sciences Announces Pricing of $40.0 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
TriSalus Life Sciences Appoints Veteran Healthcare Investor
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Second Quarter 2025 Results and Provides Updated 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces Chief Financial Officer Transition
Executive or director change · Other events · EX-99.1 to Form 8-K
TriSalus Life Sciences First Quarter 2025 Results and Provides Updated 2025 Guidance
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces $22.0 Million
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
Results of operations · EX-99.1 to Form 8-K
TriSalus Reports Q3 2024 Financial
Results of operations · EX-99.1 to Form 8-K
TriSalus Reports Q2 2024 Financial Results and Business Update
Results of operations · Shareholder vote results · EX-99.1 to Form 8-K
Completion of Exchange Offer and Consent Solicitation
Other events · EX-99.1 to Form 8-K
TriSalus Life Sciences Announces Expiration
Material agreement · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Commencement of Exchange Offer and
Other events · EX-99.1 to Form 8-K
TriSalus Reports Q1 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
TriSalus Life Sciences Secures up to $50 million
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
TriSalus Reports Q4 and Full Year 2023 Financial
Results of operations · EX-99.1 to Form 8-K
6 6 PEDD: pressure enabled drug delivery SECTION 1 Overcoming the Mechanical Barrier for Drug Delivery to Liver and Pancreatic Tumors
Results of operations · EX-99.1 to Form 8-K
TriSalus Reports Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
AGREEMENT (this “ Agreement ”) dated as of October 2, 2023 is made by and between YA II PN, LTD. ,
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
(unaudited, in thousands except share and per
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Management’s Discussion and Analysis of Financial
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
used but not defined in this Exhibit 99.3 shall have the meanings ascribed to them in this Current Report on Form 8-K (the
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
MedTech Acquisition Corporation Adjourns Special
Shareholder vote results · Other events · EX-99.1 to Form 8-K
TriSalus Life Sciences Presents Additional Data
Regulation FD disclosure · EX-99.1 to Form 8-K
We introduced new clinical data at the # ASCO23
Regulation FD disclosure · EX-99.1#2 to Form 8-K
Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD ™
Regulation FD disclosure · EX-99.1 to Form 8-K
Tweet 1: Check out TriSalus’ latest findings from the PERIO-01
Regulation FD disclosure · EX-99.2 to Form 8-K
TriSalus Life Sciences Appoints James Alecxih
Regulation FD disclosure · EX-99.1 to Form 8-K